EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predictive Value of Urine Tubular Biomarkers on Kidney Outcomes

Greco B Malijan, William G Herrington iD, Parminder K Judge iD, Rebecca J Sardell, Daniel Chapman iD, Michael Hill iD, Stewart Moffat iD, Doreen Zhu iD, Alfred K Cheung iD, Dominik Steubl, Martin J Landray, Christoph Wanner iD und 6 weitere

Clinical Journal of the American Society of Nephrology · 03.09.2026

DOI: 10.2215/cjn.0000001203 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 03.09.2026. Verfasst von Greco B Malijan und 17 weiteren Autor:innen. Beteiligte Einrichtung: Nuffield Department of Population Health, Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Ox…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim, Eli Lilly and Company, Boehringer Ingelheim, Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points The kidney failure risk equation showed excellent discrimination for treated kidney failure outcome in patients with CKD. In a wide range of causes of CKD, urine tubular biomarkers improved prediction of kidney disease progression beyond established clinical risk models. EGF, kidney injury molecule-1, and monocyte chemoattractant protein-1 added the most prognostic value.

Background

Urine tubular biomarkers have previously been associated with chronic kidney disease (CKD) progression independently of eGFR and albuminuria. We evaluated whether nine urine tubular biomarkers could improve prediction of kidney failure beyond serum creatinine and urine albumin‑creatinine ratio among adults with CKD.

Methods

Among 5100 participants in Study of Heart and Kidney Protection With Empagliflozin, a randomized trial that assessed the effects of empagliflozin 10 mg versus matching placebo among patients with CKD at risk of progression, nine urine creatinine-indexed tubular biomarkers were measured, including α ‐1 microglobulin, dickkopf-3, EGF, interleukin-18, kidney injury molecule‐1 (KIM‐1), monocyte chemoattractant protein‐1 (MCP‐1), neutrophil gelatinase-associated lipocalin, uromodulin, and human cartilage glycoprotein-40. Outcomes were kidney disease progression (treated kidney failure, renal death, or sustained ≥40% eGFR decline) and treated kidney failure (maintenance dialysis or kidney transplant). Relative to models based on the linear predictor of the kidney failure risk equation (KFRE), improvements in discrimination were estimated with further addition of the nine tubular biomarkers using absolute difference in Uno C-index.

Results

Over a median 3.5 years of follow-up, 1191 participants experienced kidney disease progression and 461 experienced treated kidney failure. KFRE demonstrated excellent discrimination for treated kidney failure (C-index 0.858 [0.840–0.874]) and moderate discrimination for kidney disease progression (0.724 [0.705–0.743]). Addition of three biomarkers (MCP-1, KIM-1, and EGF) most strongly associated with CKD outcomes yielded some further improvement in predicting kidney failure (absolute difference 0.014 [0.009–0.024]) and kidney disease progression (0.038 [0.026–0.053]). Prediction of kidney outcomes was only slightly improved when further expanding from three to all nine tubular biomarkers.

Conclusion

In a wide range of causes of CKD, adding three urine tubular biomarkers (MCP-1, KIM-1, and EGF) to KFRE improves estimates of risk of CKD progression. Clinical Trial registry name and registration number: NCT03594110.

Schlagwörter

Stichwörter der Autor:innen

CKDprediction modelingrisk factorstubular physiology

Autor:innen und Institutionen

  • Nuffield Department of Population Health, Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, United Kingdom.
  • Oxford Kidney Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
  • Nuffield Department of Population Health, Wolfson Laboratory, Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, United Kingdom.
  • Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah.
  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
  • Department of Nephrology, Hospital Rechts der Isar, Technical University of Munich, Munich, Germany.

ORCID-Profile: William G Herrington, Parminder K Judge, Daniel Chapman, Michael Hill, Stewart Moffat, Doreen Zhu, Alfred K Cheung, Christoph Wanner, Richard Haynes, Joachim H Ix, Natalie Staplin

Förderung

  • Boehringer Ingelheim, Eli Lilly and Company
  • Boehringer Ingelheim
  • Eli Lilly and Company

Zitieren

APA

Malijan, G. B., Herrington, W. G., Judge, P. K., Sardell, R. J., Chapman, D., Hill, M., Moffat, S., Zhu, D., Cheung, A. K., Steubl, D., Landray, M. J., Wanner, C., Baigent, C., Haynes, R., Ix, J. H., Staplin, N., Shlipak, M. G., & EMPA-KIDNEY Collaborative Group (2026). Predictive Value of Urine Tubular Biomarkers on Kidney Outcomes. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.0000001203

Vancouver

Malijan GB, Herrington WG, Judge PK, Sardell RJ, Chapman D, Hill M, et al. Predictive Value of Urine Tubular Biomarkers on Kidney Outcomes. Clinical Journal of the American Society of Nephrology. 2026. doi:10.2215/cjn.0000001203

BibTeX
@article{Malijan2026,
  author = {Malijan, Greco B and Herrington, William G and Judge, Parminder K and Sardell, Rebecca J and Chapman, Daniel and Hill, Michael and Moffat, Stewart and Zhu, Doreen and Cheung, Alfred K and Steubl, Dominik and Landray, Martin J and Wanner, Christoph and Baigent, Colin and Haynes, Richard and Ix, Joachim H and Staplin, Natalie and Shlipak, Michael G and EMPA-KIDNEY Collaborative Group, EMPA-KIDNEY Collaborative Group},
  title = {Predictive Value of Urine Tubular Biomarkers on Kidney Outcomes},
  journal = {Clinical Journal of the American Society of Nephrology},
  year = {2026},
  doi = {10.2215/cjn.0000001203}
}
Kostenlos starten →